Quince Therapeutics

03/30/2026

Today, Quince announced the successful settlement of our outstanding obligations under the company’s loan from the European Investment Bank. Read more here: https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-settles-approximately-164-million-debt

02/09/2026

Today, Quince announced the engagement of LifeSci Capital to serve as our exclusive financial advisor to assist in a restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Read more here: https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-engages-lifesci-capital-its-exclusive

01/29/2026

Quince announced topline results from our pivotal Phase 3 NEAT clinical trial of eDSP in Ataxia-Telangiectasia. Read more here: https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-announces-topline-results-pivotal-phase-3

01/28/2026

Quince is pleased to participate at the British Paediatric Neurology Association 2026 Annual Meeting with a poster presentation highlighting previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia. Learn more here: https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-presents-safety-data-long-term-edsp

01/26/2026

Listen in to a recent conversation Quince’s CEO & CMO Dr. Dirk Thye had with Max Brennan at The BioHub Podcast. Check it out here:

https://youtu.be/Wdyl33epIZs?si=jwprSA0hxnuD95oc

01/13/2026

Quince’s CEO & CMO Dr. Dirk Thye recently caught up with reporter Dr. Adil Ali for a wide-ranging interview produced by Onyx News, published in Fortune. Check it out here:

“All the things that attracted me to medicine were disappearing - so I changed direction.” As Dr. Dirk Thye explains, that pivot reshaped his career from clinical practice to biotech leadership, driven by a desire to rebuild impact through science.

01/12/2026

Quince Investors: Read the latest profile story on Quince Therapeutics out today on Seeking Alpha:

Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash runway—click here to read now.

01/06/2026

KOL EVENT ALERT: Don’t miss the opportunity to listen in as Citizens equity analyst Jonathan Wolleben hosts a call with expert neurologist Dr. Susan Perlman (UCLA) tomorrow January 7th at 10 a.m. Eastern Time ahead of Quince’s pivotal Phase 3 NEAT topline results – expected in middle of the first quarter of 2026 – to discuss the unmet need in Ataxia-Telangiectasia and the opportunity for our lead asset, eDSP. Register for the event here: https://www.netroadshow.com/events/login/LE9zwo3jkSOH330r9h8VQHZsqRnj7yiElIC

12/15/2025

Quince is pleased to announce that the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial of our lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patients with Ataxia-Telangiectasia. We expect to report topline results from this study in the middle of the first quarter of 2026. Read more here: https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-announces-last-patient-last-visit-phase-3

12/10/2025

Publication Alert: Quince is pleased to announce the publication of a summary of early-stage clinical studies of our Phase 3 lead asset, eDSP, in pulmonary and inflammatory bowel disorders in the scientific journal Frontiers in Drug Delivery. Read more here: https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-announces-publication-use-edsp-early-stage

12/03/2025

Quince Investors: Don’t miss the opportunity to hear our CEO & CMO Dirk Thye’s fireside chat at today’s Piper Sandler 37th Annual Healthcare Conference beginning at 10:30 a.m. Eastern Time. Listen in here: https://ir.quincetx.com/events/event-details/piper-sandler-37th-annual-healthcare-conference